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Short Communication
Fotemustine in Patients with Advanced Gastric Cancer, a 
Phase II Trial From the EORTC-GITCCG (European 
Organization for Research and Treatment of Cancer, 
Gastrointestinal Tract Cancer Cooperative Group)
Ph. Rougier.,1 C. Van Pottelsberghe,2 T. Kok, B. Paillot  ^T. Wagener, J. De Greve> 
M.C. Fabric B. Gerard/ M* Van Glabbeke,2 H. Bleiberg2 and the EORTC-GITCCG2
Gastrointestinal Unit, Gustave Roussy Institute, 94800 Villejuif, France; and 283 Av. Emmanuel Mounier,
Bruxelles 1000, Belgium
Fotemustine activity was evaluated in  26 patients, mostly pretreated, w ith advanced gastric cancer. Its 
m ain toxicity was haematological with grade 3-4 neutropenia in 32% and grade 3-4 thrombocytopenia 
in 50% of the patients, complicated by 2 toxicity-related deaths due to haemorrhage. No complete or 
partial responses were observed in the 26 eligible patients and median survival was only 11 weeks. 
Fotemustine therefore has no activity in advanced gastric cancer. Copyright © 1996 Elsevier Science Ltd
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INTRODUCTION
O n ly  a  few single cytotoxic drugs are active in advanced 
gastric cancers (AGC): mainly 5-fluorouracil, cisplatinum and 
the anthracy dines. Their activity is relatively low, producing 
an objective response in around 20% of patients, and combi­
nations of these drugs produce a maximum response rate of 
40% or less in randomised trials [1]. As some activity has 
been reported for nitrosoureas [2], the EORTC-GITCCG 
launched a phase II trial of fotemustine (Murphoran®, Ser- 
vierLab, France) a new nitrosourea [3], which has shown 
activity in advanced melanoma [4].
PATIENTS AND METHODS
Fotemustine was administered as second-line therapy in 
patients with histologically proven AGC. Eligible patients 
were not to have had previous treatment with nitrosoureas 
and no more than one previous chemotherapy regimen. 
Lesions had to be bidimensionally measureable, located out­
side previously irradiated fields, and to have progressed within 
the last 2 months. The performance status (PS) requirement 
was grade <  3 (WHO grade), and blood counts, and liver and 
renal function tests had to be normal.
Fotemustine was given as a 30 min infusion at a dose of 100
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mg/m2, on days 1 and 8 for patients having experienced 
haematological toxicity (W HO grade >  2) while on prior 
chemotherapy, and on days 1-8 and 15 for the others during 
the induction cycles [3], After a rest period of 5 weeks, 
additional cycles of fotemustine were administered at the same 
dose but once every three weeks for three cycles and then 
every 6 weeks for three further cycles. Tumour response and 
toxicity were evaluated according to W H O  criteria [5].
RESULTS
Population (Table 1)
O f the 30 patients entered, 26 were considered eligible and
4 were ineligible (inadequate PS:1; more than one previous
Table 1 . EORTC-GITCCG trial, population of patients with
advanced gastric cancer treated with fotemustine
Characteristics Number
Eligible patients (pts)
*
26/30
Sex (female/male) 3/23
Median age (years) (range) 56 (37^74)
Performance status (WHO grade)
0-1 20
2 6
Pretreated/non-pretreated patients 25/1
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CT:1; insufficient blood count:2); of the 26 patients, 1 had 
never been treated. The median number of cycles adminis­
tered was three (range 0-8) and the dose administered was 
100% ± 4% of the scheduled dose for the initial part of 
the treatment.
Toxicity
Grade 3-4 haematological toxicity was observed in 32% of 
patients for white blood cells and in 50% for platelets during 
treatment. We also observed delayed haematological toxicity 
at weeks 5-7 after discontinuation of chemotherapy in the 12 
evaluable patients with more than 35 days of follow-up after 
start of the treatment. Non-haematological toxicity was low: 
grade 2 and 3 vomiting in 24 and 16%, respectively, grade 1,
2 and 3 alopecia in 4, 4 and 8%, respectively, and general 
malaise or flu-like syndrome in 4 patients (16%). Two deaths 
were due to massive digestive haemorrhage from the tumour 
which was certainly related to grade 4 thrombocytopenia.
Responses
With W H O  criteria, no objective responses were observed, 
but 4 patients had disease stabilisation for more than 4 weeks. 
In contrast, disease in 5 patients progressed very rapidly, and
1 died of tumour progression even before administration of 
fotemustine and another after the first cycle.
Treatment was discontinued due to tumour progression in 
70% of the cases and because of toxicity in 8%. Treatment 
was interrupted in 1 patient because of pulmonary embolism.
1 patient was lost to follow-up.
Survival was short with a median of 11 weeks and a range 
of 10 days to 37+ weeks.
DISCUSSION
Fotemustine exhibited no activity on advanced gastric can­
cer in this study, although most of the paitents were, appar­
ently, in good general condition. This may be related to the 
fact that all but 1 of the patients had been pretreated, thus 
emphasising how difficult it is to assess a new drug’s activity 
for gastric cancer in a second-line setting; disease will progress 
in many patients very rapidly even before planned treatment, 
as was the case in 1 of our patients. Indeed, only 14/26 
received 3 or more cycles of chemotherapy and only 1 received 
the full course of treatment (8 cycles). W ith no response in 14 
patients, activity must be excluded in more than 15% of 
pretreated patients.
One of the reasons for such a lack of efficacy could be the
schedule used in this study. The 5-week rest period after 
induction treatment could promote tumour progression in 
these rapidly growing tumours. It is noteworthy that one 
of the most efficient chemotherapy protocols, the FAM TX 
protocol, administers chemotherapy every 2 weeks [6]. Thus, 
it cannot be excluded that another mode of administration 
(i.e. every 3 weeks) or combination with a non-haematotoxic 
drug could lead to activity in AGC, although previous trials 
using combination 5-FU and methyl-CCNU, another 
nitrosourea, yielded no significant activity [7, 8].
Although the true activity of fotemustine in untreated gas­
tric cancer has yet to be demonstrated, fotemustine with this 
schedule has clearly not improved our therapeutic armentar- 
ium in advanced gastric cancer. These results are unfortu­
nately very similar to those observed with fotemustine and the 
same protocol in advanced colorectal cancer [9].
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